Novo Nordisk A/S (NYSE:NVO) Shares Sold by Yousif Capital Management LLC

Yousif Capital Management LLC reduced its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 31.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 36,296 shares of the company's stock after selling 16,500 shares during the period. Yousif Capital Management LLC's holdings in Novo Nordisk A/S were worth $2,520,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Center for Financial Planning Inc. grew its position in Novo Nordisk A/S by 72.4% during the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after buying an additional 123 shares during the period. Strategic Investment Solutions Inc. IL boosted its stake in shares of Novo Nordisk A/S by 2,727.3% during the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after acquiring an additional 300 shares in the last quarter. Park Square Financial Group LLC acquired a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at about $29,000. Transce3nd LLC purchased a new position in shares of Novo Nordisk A/S in the 4th quarter valued at about $33,000. Finally, Kelly Lawrence W & Associates Inc. CA purchased a new position in Novo Nordisk A/S during the fourth quarter worth approximately $39,000. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Price Performance

NVO traded down $0.18 on Wednesday, reaching $74.16. 4,017,199 shares of the company's stock were exchanged, compared to its average volume of 7,055,284. Novo Nordisk A/S has a twelve month low of $57.00 and a twelve month high of $148.15. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.56 and a current ratio of 0.74. The stock's fifty day moving average price is $67.80 and its 200-day moving average price is $79.21.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting the consensus estimate of $0.92. The business had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. On average, analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on NVO shares. Dbs Bank downgraded Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. Kepler Capital Markets raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. Wall Street Zen raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Saturday. BNP Paribas began coverage on shares of Novo Nordisk A/S in a research report on Tuesday, April 15th. They set an "underperform" rating for the company. Finally, Hsbc Global Res upgraded Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, April 28th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Novo Nordisk A/S currently has an average rating of "Hold" and an average target price of $112.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.